	Pre-Clinical	Phase 1	Phase 2	Phase 3	Market
Viral Targets	TaiMed Biologics: Tamiphosphor iBio: Anti-HA Anti-NA Valeant: Virazole (ribavirin) The University of Hong Kong: Hyperimmune IVIG Quantum: Matrix Inhibitor ContraFect: CF-404 Savira: Cap Snatch/ Endonuclease NanoViricides: FluCide Crucell: CR9114 Sea Lane Biotechnologies: A06 mAb-HA Humabs BioMed: FI6v3	Sarepta Therapeutics: AVI-7100 Fab'entech: Equine Polyclonal H5 Janssen Alios BioPharma: AL-794-801 Genentech: Flu B MHAB5553A Autoimmune Technologies: Flufivitide-3 FF3	Theraclone Sciences: TCN-032 Celltrion: CT-P27 Crucell: CR8020 Visterra: VIS-410 Crucell: CR6261 Genentech: MHAA4549A Adamas: TCAD Combo MedImmune: MEDI8852 Janssen: JNJ-63623872 Roche Shionogi: S-033188 Aviragen Therapeutics: Laninamivir	MediVector: T-705 GlaxoSmithKline: Zanamivir IV National Institute of Allergy and Infectious Diseases: High titer influenza immune plasma NIH: Anti-influenza Hyperimmune IVIG	Flumadine (Rimantadine) Roche: Tamiflu NAI GlaxoSmithKline: Relenza NAI Endo Pharmaceuticals: Symmetrel (Amantadine) Daiichi-Sankyo: Inavir BioCryst Pharmaceuticals, Inc.: Rapivab Shionogi: Rapiacta
Host Targets	Pulmotect: PUL-042 ImmuneRegen: Homspera Neurokinin-1 Kineta: RIG-I agonist Therabron Therapeutics: CC10 Eisai: Eritoran	Karyopharm Therapeutics: Verdinexor Gemmus Pharma: GP1681	Ansun Biopharma: FLUDASE GlaxoSmithKline: Danirixin Beth Israel Deaconess Medical Center: Atorvastatin	Romark Laboratories, L.C.: Nitazoxanide The University of Hong Kong: Celecoxib	

Other
Inhaled
IV
Oral